Breaking News

Financial Report: Allergan

July 21, 2014

Revenues up 17% in the quarter, plans to cut 13% of workforce

2Q Revenues: $1.9 billion (+17%)

2Q Earnings: $418.4 million  (+15%)

YTD Revenues: $3.4 billion (+15%)

YTD Earnings: $676.3 million (+80%)

Comments: Total specialty pharmaceutical sales were $1.5 billion in the quarter, up 13%. Eye Care Pharmaceutical sales were $827 million, up 15%. Botox/Neuromodulators sales were $579.4 million, up 13%. Skin Care and other sales were $119.7 million, up 7%. YTD13 earnings included $259 million in costs associated with discontinued operations. Allergan will execute a restructuring in the remainder of 2014 that it estimates will deliver savings of approximately $475 million in 2015. As part of the restructuring, Allergan will reduce its workforce by approximately 1,500 employees, or approximately 13%.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision